BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT

Bioxytran, Inc. (OTC: BIXT), a biotechnology company focused on developing therapies for hypoxia-related conditions and viral diseases, has successfully completed a private placement financing, garnering gross proceeds of approximately $1.2 million. Announced on March 20, 2026, the financing closed on March 18, 2026, resulting in the issuance of roughly 21,071,667 shares of common stock at about $0.055 per share. Additionally, investors received warrants to acquire up to 19,750,001 more shares at an exercise price of $0.12 per share, which are valid for five years.

The private placement was conducted under an exemption from registration as outlined in Section 4(a)(2) of the Securities Act of 1933 and Regulation D. This financing strategy not only strengthens Bioxytran's balance sheet but also aligns with the company's efforts to propel its key development initiatives forward. CEO David Platt, PhD, expressed confidence that the funds will support both working capital and the advancement of ongoing development programs, along with selected commercialization efforts.

Bioxytran plans to leverage these proceeds for the imminent market introduction of A-SUQAR®, a plant-derived dietary supplement expected to launch in the current quarter. This initiative demonstrates the company’s dual-track approach: pursuing immediate commercial opportunities alongside the long-term advancement of its pharmaceutical programs.

The issued warrants also present a potential avenue for additional funding through future exercises, which could further bolster the company's growth prospects. Bioxytran focuses on addressing significant unmet medical needs with a unique galectin-targeting platform that spans various therapeutic areas, including infectious diseases, metabolic health, and inflammation. As Bioxytran moves forward, ongoing developments will be closely monitored by investors and stakeholders alike.

Bioxytran, Inc. (OTC: BIXT) recently completed a private placement financing of approximately $1.2 million, issuing over 21 million shares at a price of $0.055 each, along with warrants that could further bolster the company’s capital. The strategic use of these funds—aimed at strengthening operational capacity and advancing key developmental initiatives—positions Bioxytran favorably in the biotechnology sector, where the swift commercialization of innovative therapies is crucial.

The company’s focus on hypoxia and viral diseases aligns with growing market demands for solutions targeting these pressing health challenges. The imminent launch of A-SUQAR®, a plant-derived dietary supplement, indicates a well-thought-out dual-track approach that balances immediate revenue generation with long-term pharmaceutical development. This could potentially enhance investor confidence as Bioxytran seeks to diversify its product portfolio and reduce reliance on any single revenue stream.

From a financial perspective, the issuance of warrants at an attractive exercise price of $0.12 per share could signal confidence from investors in the company’s future. These warrants, with a five-year term, provide the company with a mechanism for additional fundraising without immediate dilution, assuming successful exercise by warrant holders.

However, potential investors should remain cautious. Although Bioxytran's initiatives hold promise, the biotechnology sector is inherently risky, characterized by fluctuating market sentiments and substantial developmental hurdles. The company’s reliance on future commercialization and advancement of clinical programs carries uncertainties. Investors should weigh these factors against the potential rewards of investing in a company positioned in a niche space of significant unmet medical need.

In summary, while the recent financing strengthens Bioxytran’s foundations, potential investors should closely monitor developments regarding product launches and clinical advancements while preparing for the volatility that often accompanies biotech investments.